Risdiplam - PTC Therapeutics/Roche
Alternative Names: Evrysdi; EvrysdiTM; RG-7916; RO-7034067Latest Information Update: 14 Nov 2024
Price :
$50 *
At a glance
- Originator PTC Therapeutics
- Developer Chugai Pharmaceutical; PTC Therapeutics; Roche
- Class 2 ring heterocyclic compounds; Imidazoles; Pyridazines; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action Survival of motor neuron 2 protein expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Spinal muscular atrophy
Most Recent Events
- 14 Nov 2024 Launched for Spinal muscular atrophy (In adolescents, In children, In adults, In infants) in Canada (PO) before November 2024
- 14 Nov 2024 Launched for Spinal muscular atrophy (In adolescents, In children, In infants, In adults) in Finland, Australia (PO) before November 2024
- 14 Nov 2024 Launched for Spinal muscular atrophy (In adolescents, In children, In infants, In adults) in Norway, Sweden, Hungary (PO) before November 2024